Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC)
- PMID: 35904048
- PMCID: PMC9766881
- DOI: 10.1093/clinchem/hvac117
Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC)
Abstract
Background: Diabetes exerts adverse effects on the heart, and a longer diabetes duration is associated with greater heart failure risk. We studied diabetes duration and subclinical myocardial injury, as reflected by high-sensitivity cardiac troponin (hs-cTnT).
Methods: We analyzed 9052 participants without heart failure or coronary heart disease (mean age 63 years, 58% female, 21% Black, 15% with diabetes) at The Atherosclerosis Risk in Communities Study (ARIC) Visit 4 (1996 to 1998). Diabetes duration was calculated based on diabetes status at Visits 1 (1987 to 1989) through 4, or using self-reported age of diabetes diagnosis prior to Visit 1. We used multinomial logistic regression to determine the association of diabetes duration with increased (≥14 ng/L) or detectable (≥6 ng/L) Visit 4 hs-cTnT, relative to undetectable hs-cTnT, adjusted for demographics and cardiovascular risk factors.
Results: The prevalence of increased Visit 4 hs-cTnT was higher in persons with longer diabetes duration, from 12% for those with diabetes 0 to <5 years up to 31% among those with diabetes for ≥15 years (P for trend <0.0001). New onset diabetes at Visit 4 was associated with 1.92× higher relative risk (95% CI, 1.27-2.91) of increased hs-cTnT than no diabetes. Longer diabetes duration was associated with greater myocardial injury, with duration ≥15 years associated with 9.29× higher risk (95% CI, 5.65-15.29) for increased hs-cTnT and 2.07× (95% CI, 1.24-3.16) for detectable hs-cTnT, compared to no diabetes.
Conclusions: Longer diabetes duration is strongly associated with subclinical myocardial injury. Interventional studies are needed to assess whether the prevention and delay of diabetes onset can mitigate early myocardial damage.
© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Figures
Comment in
-
Cardiac Troponin as a Marker of Heart Failure Risk in Diabetes.Clin Chem. 2022 Oct 6;68(10):1232-1234. doi: 10.1093/clinchem/hvac124. Clin Chem. 2022. PMID: 35897125 No abstract available.
References
-
- Centers for Disease Control and Prevention. National Diabetes Statistics Report https://www.cdc.gov/diabetes/data/statistics-report/index.html. (Accessed May 2022).
-
- Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 2018;28: 1081–91. - PubMed
-
- Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254–61. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K24 HL152440/HL/NHLBI NIH HHS/United States
- T32 HL007024/HL/NHLBI NIH HHS/United States
- HHSN268201700001I/HL/NHLBI NIH HHS/United States
- HHSN268201700004I/HL/NHLBI NIH HHS/United States
- 75N92022D00003/HL/NHLBI NIH HHS/United States
- R01 HL146907/HL/NHLBI NIH HHS/United States
- HHSN268201700003I/HL/NHLBI NIH HHS/United States
- R01 DK089174/DK/NIDDK NIH HHS/United States
- HHSN268201700004C/HB/NHLBI NIH HHS/United States
- HHSN268201700005C/HL/NHLBI NIH HHS/United States
- HHSN268201700001C/HL/NHLBI NIH HHS/United States
- HHSN268201700002C/HB/NHLBI NIH HHS/United States
- HHSN268201700003C/HL/NHLBI NIH HHS/United States
- K23 HL153774/HL/NHLBI NIH HHS/United States
- HHSN268201700002I/HL/NHLBI NIH HHS/United States
- HHSN268201700005I/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
